Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivosidenib - Servier

Next Previous
Drug Profile

Ivosidenib - Servier

Alternative Names: Tuoshuvo; AG-120; CS 3010; ivonib tablet; S-95031; TIBSOVO; Tibsovo; Tosuvo; Tuoshuwo

Latest Information Update: 02 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Bristol-Myers Squibb; CStone Pharmaceuticals; HOVON Foundation; Servier; University of Pittsburgh Medical Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Acute myeloid leukaemia; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Cholangiocarcinoma; Myelodysplastic syndromes
  • Phase III Chondrosarcoma
  • Phase II Glioma; Solid tumours

Most Recent Events

  • 12 Feb 2026 Servier terminates a phase I/II trial in Cholangiocarcinoma (Combination therapy, Metastatic disease, Second line therapy or greater) in USA, United Kingdom (PO) due to sponsors decision (NCT05921760)
  • 14 Jan 2026 Servier initiates enrolment in a phase I pharmacokinetics trial in Australia, Brazil, Czech Republic, South Korea, Spain and USA (PO) (NCT07006688)
  • 06 Dec 2025 Adverse events and efficacy data from the phase-III ALIDHE trial in Acute myeloid leukemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top